Blinklab Limited (AU:BB1) has released an update.
BlinkLab Limited has announced a collaborative study with Monash University aimed at exploring the effects of ketamine on cognition, which could influence treatments for psychiatric conditions like depression, schizophrenia, and PTSD. The research will utilize BlinkLab’s AI-powered diagnostic tests to monitor changes in cognitive processes, potentially aiding future cognitive behavioral therapy. This groundbreaking study offers a chance to enhance our understanding of cognitive mechanisms and develop new therapies for various mental health disorders.
For further insights into AU:BB1 stock, check out TipRanks’ Stock Analysis page.
